WO1994012158A1 - Controlled release growth hormone containing microspheres - Google Patents
Controlled release growth hormone containing microspheres Download PDFInfo
- Publication number
- WO1994012158A1 WO1994012158A1 PCT/US1993/011621 US9311621W WO9412158A1 WO 1994012158 A1 WO1994012158 A1 WO 1994012158A1 US 9311621 W US9311621 W US 9311621W WO 9412158 A1 WO9412158 A1 WO 9412158A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polymer
- growth hormone
- poly
- microspheres
- lactide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/839—Nerves; brain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
- Y10T428/2985—Solid-walled microcapsule from synthetic polymer
Definitions
- This invention generally relates to polymeric microspheres for controlled release of growth hormone.
- hGH Human Growth hormone
- the protein contains 191 amino acids and has a molecular weight of 22,000.
- hGH causes growth of all tissues of the body which are capable of growth.
- the hormone is involved in the following metabolic effects: l) increased cellular protein synthesis, 2) decreased glucose utilization, and 3) increased mobilization of fatty acids from adipose tissue.
- hGH is used to treat hypopituitary dwarfism and is administered three times per week by the subcutaneous or intramuscular route.
- growth hormone generally necessitates frequent intramuscular (IM) or subcutaneous (SQ) injections.
- IM intramuscular
- SQL subcutaneous
- the advantages of a controlled release formulation for growth hormone include increased patient compliance and acceptance by reducing the number of injections, increased therapeutic benefit by eliminating the peak and valley changes in blood levels, and potentially lowering the total administered amount of drug by reducing peaks and valleys.
- One means for controlling blood levels of a compound is to administer it in the form of a polymeric matrix that releases compound as a function of polymer degradation and/or drug diffusion.
- a variety of biodegradable and non-biodegradable polymers have been used for such applications, including polyesters such as poly(lactide-co-glycolide) ⁇ , polyanhydrides, polyorthoesters, and ethylenevinyl acetate polymers.
- release is controlled by selection of the appropriate polymer, encapsulation conditions, and drug loading and excipients. Examples of these polymeric systems are described in U.S. Patent Nos.
- the conditions used to encapsulate the drug must not result in degradation of the drug to be delivered nor must the drug react with the polymeric matrix so as to inactivate or bind the drug.
- the delivery means must be cost effective to produce, stable to storage, and administrable using standard methodology.
- the growth hormone polymeric controlled release systems are described wherein the growth hormone retains good biological activity and is released over an extended period of time following administration.
- the growth hormone polymeric microspheres are made using very cold temperatures to freeze the polymer-growth hormone mixtures into polymeric microspheres with very high retention of biological activity and material.
- Polymer preferably a poly(lactide)
- a solvent such as methylene chloride together with powdered growth hormone.
- the polymer/growth hormone mixture is atomized into a vessel containing a frozen non-solvent such as ethanol, overlayed with a liquified gas such as nitrogen, at a temperature below the freezing point of the polymer/active agent solution or suspension.
- the atomized particles freeze into microspheres upon contacting the cold liquified gas, then sink onto the frozen non-solvent layer.
- the frozen non-solvent is then thawed.
- the non-solvent thaws the microspheres are still frozen and sink into the liquid non-solvent.
- the solvent in the microspheres also thaws and is slowly extracted into the non-solvent, resulting in hardened microspheres containing the growth hormone.
- Examples using human growth hormone show sustained release of biologically active growth hormone when the microspheres are tested in vitro or in vivo, extending over a period of one day up to three months. Altered release can be achieved by inclusion of polymer degradation modifiers, pore forming agents, and stabilizers of the growth hormone.
- Figure 1 is a graph of the average change in weight (g) over 14 days for rats administered 80 ⁇ g growth hormone daily (dark circles) , 20 ⁇ g growth hormone daily (open squares) , and growth hormone released from microspheres (dark squares) over time (days) .
- Growth hormone containing microspheres are made by incorporating the growth hormone into a biocompatible polymeric microsphere, up to approximately 50% w/w, wherein the microsphere containing the growth hormone is characterized by sustained controlled release of the growth hormone over a period of at least 24 hours up to a period of one to three months.
- the polymer is biodegradable, most preferably by hydrolysis
- the microspheres have a diameter of less than one hundred eighty microns, most preferably less than seventy microns, and are suitable for administration by injection subcutaneously or intramuscularly (a size suitable for injection through a 23-gauge needle would be less than 180 ⁇ in diameter)
- the microspheres contain from 0.01% by weight up to approximately 50% by weight human growth hormone.
- microsphere is used to mean solid spheres formed of polymer having growth hormone dispersed throughout, as well as microparticulates and microcapsules, unless otherwise noted. Microparticulates are specifically referred to when describing irregularly shaped polymer or polymer-drug particles. Microcapsules are spherical shaped polymer devices having a non-polymer core or a core of a different polymer than the outer shell.
- sustained or extended release of the growth hormone can be continuous or discontinuous, linear or non-linear. This can be accomplished using one or more types of polymer compositions, drug loadings, selections of excipients or degradation enhancers, or other modifications, administered alone, in combination or sequentially to produce the desired effect.
- Growth hormone is available in the form of a lyophilized powder containing physiological buffers and salts.
- Spray drying In spray drying, the polymer and growth hormone are mixed together in a solvent for the polymer, then the solvent is evaporated by spraying the solution, leaving polymeric droplets containing the active agent.
- Spray drying is reviewed in detail by K. Masters in “Spray Drying Handbook” (John Wiley & Sons, New York 1984) ; and Patrick B. Deasy in “Microencapsulation and Related Drug Processes” (Marcel Dekker, Inc., New York 1984) , the teachings of which are incorporated herein. Spray drying is not preferred since it may result in some loss of activity due to the heat generated in the process as well as in loss of considerable amounts of the material due to sticking of the polymer to the large surface area on the sides of the chamber.
- Solvent evaporation techniques can be used to form microspheres. These techniques involve dissolving the polymer in an organic solvent which contains either dissolved or dispersed active agent. The polymer/active agent solution is then added to an agitated continuous phase which is usually aqueous. Emulsifiers are included in the aqueous phase to stabilize the oil-in- water emulsion. The organic solvent is then evaporated over a period of several hours or more, thereby depositing the polymer around the core material. Solvent can be removed from the microspheres in a single step, as described in U.S. Patent No. 3,737,337 and U.S. Patent No. 3,523,906, or in U.S. Patent No.
- Solvent evaporation works reasonably well but is not preferred since the amount of incorporated material is usually lower than the theoretical values due to loss of drug to the aqueous phase, as reported by Benita, et al., in "Characterization of Drug Loaded Poly(d,l- lactide) Microspheres," J. Pharm. Sci. 73, 1721-1724 (1984) .
- Phase separation techniques can also be used to form microspheres. These techniques involve the formation of a water-in-oil emulsion or oil in water emulsion.
- the polymer is precipitated from the continuous phase onto the active agent by a change in temperature, pH, ionic strength or the addition of precipitants.
- U.S. Patent No. 4,675,800, et al. describes the formation of poly(lactic-co- glycolic) acid microspheres containing active proteins.
- the protein is first dissolved in the aqueous phase of a water-in-oil emulsion or dispersed as a solid in the polymer phase. Polymer is then precipitated around the aqueous droplets or drug particles by addition of a non- solvent for the polymer such as silicone oil.
- Microcapsules contain a core material surrounded by a polymer membrane capsule. Microcapsules are not the preferred embodiment for delivery of growth hormone, however, since the release kinetics of active agents from these devices can be difficult to control.
- phase separation techniques result in the formation of microspheres containing active agents, active agent is often lost during the solvent extraction process.
- biologically active proteins may be denatured during the process. Rapid freezing, solvent extraction
- Polymer and agent to be encapsulated in solution are atomized using an ultrasonic device into a liquified gas.
- the atomized particles freeze when they contact the liquified gas (liquid nitrogen) , forming frozen spheres. These sink to the surface of the frozen non- solvent (ethanol) .
- the liquid gas is evaporated and the spheres begin to sink into the non-solvent as the non- solvent thaws.
- the solvent in the spheres is extracted into the non-solvent to form microspheres containing the agent to be encapsulated.
- Other non-solvents such as hexane are added to the non-solvent (ethanol) to increase the rate of solvent extraction from certain polymers, where appropriate, for example, when spheres are formed of polylactide-co-glycolide polymers.
- Oxygen is not preferred since it is explosive and may cause oxidation of the protein.
- a cold non-solvent for the polymer can be substituted for the combination of liquified gas- frozen no-solvent, provided the temperature of the non- solvent is below the freezing temperature of the polymer/active agent solution.
- the polymer/active agent freeze immediately upon contacting the cold liquid, and then be slowly thawed and the polymer solvent extracted from the microspheres.
- the thawing rate is dependent on the choice of solvents and non-solvents. It is important to select a solvent for the polymer having a higher melting point than the non-solvent for the polymer so that the non- solvent melts first, allowing the frozen microspheres to sink into the liquid where they later thaw. If a cold liquid non-solvent system for making the polymeric microspheres is used, the microspheres will sink immediately into the non-solvent. As the solvent in the microsphere thaws, it is extracted into the non-solvent. The solvent for the polymer and the non-solvent for the polymer must be miscible to allow extraction of the solvent from the microspheres. Table 1 shows some polymer/solvent/non-solvent systems that can be used in this process along with their melting points.
- Chloride (-95.1) Chloroform (-63.5) Methanol (-97.5)
- the polymer/active agent/solvent mixture can be sprayed into the cold liquid, either the liquified gas or the cold non-solvent, using a variety of devices which can be used to form small particles, including sonic nozzles, pressure nozzles, pneumatic nozzles and rotary atomizers.
- a wide range of sizes of microspheres can be made by varying the droplet size, for example, by changing the nozzle diameter. If very large spheres are desired, the spheres can be extruded through a syringe directly into the cold liquid. Increasing the inherent viscosity of the polymer solution can also result in an increasing microspheres size.
- the size of the spheres produced by this process can range from greater than 1000 to 5 microns in diameter.
- a preferred size range for injectable microspheres is from 30 to 180 microns in diameter.
- the microspheres made by this technique are spherical in shape. Selection of the Polymeric Matrix
- Polymers that can be used to form the microspheres include bioerodible polymers such as poly(lactide) , poly(lactide-co-glycolide) , poly(caprolactone) , polycarbonates, polyamides, polyanhydrides, polyamino acids, polyortho esters, polyacetals, polycyanoacrylates and degradable polyurethanes, and non-erodible polymers such as polyacrylates, ethylene-vinyl acetate polymers and other acyl substituted cellulose acetates and derivatives thereof, non-erodible polyurethanes, polystyrenes, polyvinyl chloride, polyvinyl fluoride, poly(vinyl imidazole) , chlorosulphonated polyolifins, and polyethylene oxide.
- bioerodible polymers such as poly(lactide) , poly(lactide-co-glycolide) , poly(caprolactone) , polycarbonates, polyamides,
- a polymer solution is prepared containing between 1% polymer and 30% polymer, preferably 5-10% polymer.
- a poly(lactide) is used.
- this term includes polymers of lactic acid or lactide alone, copolymers of lactic acid and glycolic acid, copolymers of lactide and glycolide, mixtures of such polymers and copolymers, the lactic acid or lactide being either in racemic or optically pure form. It is most desirable to use polylactides in the range of molecular weight up to 100,000.
- the release of the growth hormone from these polymeric systems can occur by two different mechanisms.
- the drug can be released by diffusion through aqueous filled channels generated in the dosage form by the dissolution of the drug or by voids created by the removal of the polymer solvent during the original microencapsulation.
- the second mechanism is enhanced release due to the degradation of the polymer. With time the polymer begins to erode and generates increased porosity and microstructure within the device. This creates additional pathways for drug release.
- the degradation of the polymers occurs by spontaneous hydrolysis of the ester linkages on the backbone.
- the rate can be controlled by changing polymer properties influencing water uptake. These include the monomer ratio (lactide to glycolide) , the use of L-Lactide as opposed to D/L Lactide, and the polymer molecular weight. These factors determine the hydrophilicity and crystallinity which ultimately govern the rate of water penetration. Hydrophilic excipients such as salts, carbohydrates and surfactants can also be incorporated to increase water penetration into the devices and thus accelerate the erosion of the polymer.
- the release rate can also be controlled by varying the loading of growth hormone within the microspheres. Increasing the loading will increase the network of interconnecting channels formed upon the dissolution of the drug and enhance the release of drug from the microspheres.
- the preferred range of growth hormone loadings is in the range of 3-30% (w/w) .
- Polymer hydrolysis is accelerated at acidic or basic pH's and thus the inclusion of acidic or basic excipients can be used to modulate the polymer erosion rate.
- the excipients can be added as particulates, can be mixed with the incorporated growth hormone or can be dissolved within the polymer.
- Excipients can be also added to the growth hormone to maintain its potency depending on the duration of release.
- Stabilizers include carbohydrates, amino acids, fatty acids, and surfactants and are known to those skilled in the art.
- excipients which modify the solubility of growth hormone such as salts, complexing agents (albumin, protamine) can be used to control the release rate of the protein from the microspheres.
- Stabilizers for the growth hormone are based on ratio to the protein on a weight basis.
- examples include carbohydrate such as sucrose, lactose, mannitol, dextran, and heparin, proteins such as albumin and protamine, amino acids such as arginine, glycine, and threonine, surfactants such as TweenTM and PluronicTM, salts such as calcium chloride and sodium phosphate, and lipids such as fatty acids, phospholipids, and bile salts.
- the ratios are generally 1:10 to 4:1, carbohydrate to protein, amino acids to protein, protein stabilizer to protein, and salts to protein; 1:1000 to 1:20, surfactant to protein; and 1:20 to 4:1, lipids to protein.
- Degradation enhancers are based on weight relative to the polymer weight. They can be added to the protein phase, added as a separate phase (i.e., as particulates) or can be codissolved in the polymer phase depending on the compound. In all cases the amount should be between 0.1 and thirty percent (w/w, polymer).
- Types of degradation enhancers include inorganic acids such as ammonium sulfate and ammonium chloride, organic acids such as citric acid, benzoic acids, heparin, and ascorbic acid, inorganic bases such as sodium carbonate, potassium carbonate, calcium carbonate, zinc carbonate, and zinc hydroxide, and organic bases such as protamine sulfate, spermine, choline, ethanolamine, diethanolamine, and triethanolamine and surfactants such as TweenTM and PluronicTM.
- inorganic acids such as ammonium sulfate and ammonium chloride
- organic acids such as citric acid, benzoic acids, heparin, and ascorbic acid
- inorganic bases such as sodium carbonate, potassium carbonate, calcium carbonate, zinc carbonate, and zinc hydroxide
- organic bases such as protamine sulfate, spermine, choline, ethanolamine, diethanolamine, and triethanolamine and surfactants such as TweenTM and Pl
- Pore forming agents to add microstructure to the matrices i.e., water soluble compounds such as inorganic salts and sugars. They are added as particulates. The range should be between one and thirty percent (w/w, polymer) . Administration of the microspheres to a patient.
- microspheres containing growth hormone are administered to a patient by injection subcutaneously, intramuscularly, intraperitoneally, and intrader ally, by administration to mucosal membranes (such as intranasally or by means of a suppository) , or by in situ delivery to provide the desired dosage of growth hormone, based on the known parameters for treatment with growth hormone of the various medical conditions.
- the present invention is further described by the following non-limiting examples.
- Example 1 Preparation of poly(L-lactic acid) microspheres containing growth hormone.
- the polymer protein mixture was pumped from the syringe via a syringe pump at 2 ml/min, into an ultrasonic nozzle (Mode, Sonics and Material, Danbury CT) that was placed above the container of liquid nitrogen and frozen ethanol.
- the nozzle atomized the suspension into droplets which froze upon contact with the liquid nitrogen and formed microspheres which sank onto the frozen ethanol.
- Example 2 In vivo assay of growth hormone released from poly(D/L-lactide co-glycolide) microspheres.
- Microspheres as produced in example 1 were tested in the rat bioassay detailed in the British Pharmacopeia. Hypophysecto ized rats were obtained from Taconics, Germantown, New York. Three groups of animals were utilized. Groups 1 and 2 received a single daily injection of hGH of 20 and 80 ⁇ g respectively. Group 3 received 18 mg of microspheres injected subcutaneously in the dorsu . The animals were fed with a standard diet and allowed free access to water.
- the increase in body weight is shown in Figure 1.
- the injectable formulation provides sustained release of potent hormone which results in body weight gain.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES94902475T ES2151541T3 (en) | 1992-12-02 | 1993-12-02 | MICROSPHERES CONTAINING HORMONE OF THE GROWTH OF PROLONGED LIBERATION. |
JP6513463A JPH08503950A (en) | 1992-12-02 | 1993-12-02 | Microspheres containing sustained release growth hormone |
AU56835/94A AU670168B2 (en) | 1992-12-02 | 1993-12-02 | Controlled release growth hormone containing microspheres |
DK94902475T DK0674506T3 (en) | 1992-12-02 | 1993-12-02 | Controlled release growth hormone-containing microspheres |
AT94902475T ATE195652T1 (en) | 1992-12-02 | 1993-12-02 | CONTROLLED RELEASE MICROSPHERES CONTAINING GROWTH HORMONE |
CA002150803A CA2150803C (en) | 1992-12-02 | 1993-12-02 | Controlled release growth hormone containing microspheres |
DE69329295T DE69329295T2 (en) | 1992-12-02 | 1993-12-02 | GROWTH HORMONE CONTAINING MICROSPHERES WITH CONTROLLED RELEASE |
EP94902475A EP0674506B1 (en) | 1992-12-02 | 1993-12-02 | Controlled release growth hormone containing microspheres |
GR20000402562T GR3034873T3 (en) | 1992-12-02 | 2000-11-16 | Controlled release growth hormone containing microspheres. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98432392A | 1992-12-02 | 1992-12-02 | |
US984,323 | 1992-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994012158A1 true WO1994012158A1 (en) | 1994-06-09 |
Family
ID=25530460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/011621 WO1994012158A1 (en) | 1992-12-02 | 1993-12-02 | Controlled release growth hormone containing microspheres |
Country Status (13)
Country | Link |
---|---|
US (6) | US5654010A (en) |
EP (2) | EP1013270A3 (en) |
JP (1) | JPH08503950A (en) |
KR (1) | KR19990022038A (en) |
AT (1) | ATE195652T1 (en) |
AU (2) | AU670168B2 (en) |
CA (1) | CA2150803C (en) |
DE (1) | DE69329295T2 (en) |
DK (1) | DK0674506T3 (en) |
ES (1) | ES2151541T3 (en) |
GR (1) | GR3034873T3 (en) |
PT (1) | PT674506E (en) |
WO (1) | WO1994012158A1 (en) |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995029664A1 (en) * | 1994-05-03 | 1995-11-09 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
WO1996007399A1 (en) * | 1994-09-09 | 1996-03-14 | Takeda Chemical Industries, Ltd. | Sustained release preparation containing metal salt of a peptide |
WO1996040072A2 (en) * | 1995-06-07 | 1996-12-19 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of human growth hormone |
WO1996040074A2 (en) * | 1995-06-07 | 1996-12-19 | Alkermes Controlled Therapeutics, Inc. | Device for releasing aggregation-stabilized, biologically active agent |
WO1997007788A2 (en) * | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
AU679150B1 (en) * | 1996-01-10 | 1997-06-19 | Lg Chemical Ltd. | Sustained-release formulation of animal growth hormone and process for preparation thereof |
US5654010A (en) * | 1992-12-02 | 1997-08-05 | Alkermes, Inc. | Composition for sustained release of human growth hormone |
US5674534A (en) * | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
US5711968A (en) * | 1994-07-25 | 1998-01-27 | Alkermes Controlled Therapeutics, Inc. | Composition and method for the controlled release of metal cation-stabilized interferon |
US5716644A (en) * | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
WO1998024427A2 (en) * | 1996-12-02 | 1998-06-11 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing inflammatory diseases |
WO1998027980A2 (en) * | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
US5912015A (en) * | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US6087324A (en) * | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
WO2000052049A2 (en) * | 1999-03-01 | 2000-09-08 | Alkermes Controlled Therapeutics, Inc. | A method for purifying human growth hormone |
US6120787A (en) * | 1995-10-19 | 2000-09-19 | Biogram Ab | Sustained release particles |
US6190702B1 (en) | 1996-03-28 | 2001-02-20 | Takeda Chemical Industries, Ltd. | Sustained-released material prepared by dispersing a lyophilized polypeptide in an oil phase |
US6191107B1 (en) | 1997-09-26 | 2001-02-20 | Takeda Chemical Industries, Ltd. | Complex of human growth hormone and zinc |
EP1080718A1 (en) * | 1995-06-07 | 2001-03-07 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of human growth hormone |
US6267981B1 (en) | 1995-06-27 | 2001-07-31 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
US6306826B1 (en) | 1997-06-04 | 2001-10-23 | The Regents Of The University Of California | Treatment of heart failure with growth hormone |
US6482864B1 (en) | 1998-03-20 | 2002-11-19 | Takeda Chemical Industries, Ltd. | Sustained-release preparation of physiologically active polypeptide and production thereof |
US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
WO2003000282A1 (en) * | 2001-06-21 | 2003-01-03 | Genentech, Inc. | Sustained release formulation |
US6514533B1 (en) | 1992-06-11 | 2003-02-04 | Alkermas Controlled Therapeutics, Inc. | Device for the sustained release of aggregation-stabilized, biologically active agent |
US6573238B2 (en) | 1997-11-07 | 2003-06-03 | Chiron Corporation | Method for producing sustained-release formulations |
US6616949B2 (en) | 2000-11-16 | 2003-09-09 | Jagotec Ag | Process for producing microparticles |
US6616948B2 (en) | 2000-10-06 | 2003-09-09 | Jagotec Ag | Starch |
US6692770B2 (en) | 2000-10-06 | 2004-02-17 | Jagotec Ag | Starch microparticles |
US6723347B1 (en) | 1999-09-17 | 2004-04-20 | Takeda Chemical Industries, Ltd. | Proces for producing protein powder |
WO2005034988A1 (en) * | 2003-10-10 | 2005-04-21 | Novo Nordisk A/S | Long-acting molecules in sustained release formulations |
US6936278B2 (en) | 2002-03-21 | 2005-08-30 | Jagotec Ag | Microparticles |
US6992065B2 (en) | 2000-04-19 | 2006-01-31 | Genentech, Inc. | Sustained release formulations |
US7033609B2 (en) | 2000-10-06 | 2006-04-25 | Jagotec Ag | Microparticle preparation |
EP1691826A1 (en) * | 2003-11-14 | 2006-08-23 | ALZA Corporation | Excipients in drug delivery vehicles |
US7105181B2 (en) | 2001-10-05 | 2006-09-12 | Jagotec, Ag | Microparticles |
EP2176321A2 (en) * | 2007-08-07 | 2010-04-21 | Korea Research Institute of Bioscience and Biotechnology | Porous polymer particles immobilized with charged molecules and method for preparing the same |
US7713739B1 (en) | 2000-11-17 | 2010-05-11 | Novartis Vaccines And Diagnostics, Inc. | Microparticle-based transfection and activation of dendritic cells |
EP2286792A1 (en) | 1999-02-26 | 2011-02-23 | Novartis Vaccines and Diagnostics, Inc. | Microemulsions with an adsorbent surface, comprising a microdroplet emulsion |
US9149440B2 (en) | 2003-09-02 | 2015-10-06 | University Of South Florida | Nanoparticles for drug-delivery |
Families Citing this family (237)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US6080429A (en) * | 1993-10-25 | 2000-06-27 | Genentech, Inc. | Method for drying microspheres |
US6913767B1 (en) | 1993-10-25 | 2005-07-05 | Genentech, Inc. | Compositions for microencapsulation of antigens for use as vaccines |
DK0959873T3 (en) * | 1996-12-20 | 2006-07-03 | Alza Corp | Gel composition and methods |
US5989463A (en) * | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US20020017295A1 (en) * | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
SE512663C2 (en) | 1997-10-23 | 2000-04-17 | Biogram Ab | Active substance encapsulation process in a biodegradable polymer |
JP2001507722A (en) * | 1997-11-06 | 2001-06-12 | オーボン コーポレイション | Stabilized dry pharmaceutical compositions for drug delivery and methods of preparing the same |
US6168570B1 (en) * | 1997-12-05 | 2001-01-02 | Micrus Corporation | Micro-strand cable with enhanced radiopacity |
NZ525914A (en) | 1998-03-10 | 2004-03-26 | Genentech Inc | Novel polypeptides and nucleic acids encoding the same |
US20030180368A1 (en) * | 1998-03-14 | 2003-09-25 | Cenes Drug Delivery Limited | Production of microparticles |
ES2359973T3 (en) | 1998-03-19 | 2011-05-30 | MERCK SHARP & DOHME CORP. | LIQUID POLYMER COMPOSITIONS FOR THE CONTROLLED RELEASE OF BIOACTIVE SUBSTANCES. |
US6284282B1 (en) * | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
EP3112468A1 (en) | 1998-05-15 | 2017-01-04 | Genentech, Inc. | Il-17 homologous polypeptides and therapeutic uses thereof |
PT1076703E (en) | 1998-05-15 | 2007-10-10 | Genentech Inc | Therapeutic uses of il-17 homologous polypeptides |
US20020172678A1 (en) | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
US6696063B1 (en) * | 1998-12-30 | 2004-02-24 | Applied Research Systems Ars Holding N.V. | Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy |
US7018654B2 (en) * | 1999-03-05 | 2006-03-28 | New River Pharmaceuticals Inc. | Pharmaceutical composition containing an active agent in an amino acid copolymer structure |
US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US6444223B1 (en) | 1999-05-28 | 2002-09-03 | Alkermes Controlled Therapeutics, Inc. | Method of producing submicron particles of a labile agent and use thereof |
AU779277B2 (en) * | 1999-06-04 | 2005-01-13 | Alza Corporation | Implantable gel compositions and method of manufacture |
EP1949890A3 (en) | 1999-06-04 | 2011-05-18 | ALZA Corporation | Implantable gel compositions and method of manufacture |
US6586011B2 (en) | 1999-06-10 | 2003-07-01 | Southpac Trust International, Inc. | Microencapsulated plasminogen activators |
AU5152700A (en) | 1999-06-15 | 2001-01-02 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6310166B1 (en) | 1999-08-12 | 2001-10-30 | Closure Medical Corporation | Sterilized cyanoacrylate solutions containing thickeners |
FR2797784B1 (en) * | 1999-08-27 | 2001-11-30 | Mainelab | PROCESS FOR THE ENCAPSULATION OF ACTIVE MATERIALS BY COACERVATION OF POLYMERS IN NON-CHLORINE ORGANIC SOLVENT |
ES2252048T3 (en) * | 1999-09-16 | 2006-05-16 | Novo Nordisk A/S | COMPOSITION FOR IVF. |
US6458387B1 (en) * | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
US6284283B1 (en) | 1999-10-21 | 2001-09-04 | Alkermes Controlled Therapeutics, Inc. | Method of producing sub-micron particles of biologically active agents and uses thereof |
JP2004522404A (en) | 1999-12-01 | 2004-07-29 | ジェネンテック・インコーポレーテッド | Secreted and transmembrane polypeptides and nucleic acids encoding them |
US20040071715A1 (en) * | 1999-12-15 | 2004-04-15 | Schwendeman Steven P. | Polymer compositions that stabilize and control the release of formaldehyde-treated vaccine antigens |
US6743446B2 (en) | 1999-12-15 | 2004-06-01 | The Ohio State University Research Foundation | Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers |
EP2163625B1 (en) | 1999-12-23 | 2014-05-21 | Genentech, Inc. | IL-17 and IL-17R homologous polypeptides and therapeutic uses thereof |
EP1246917B1 (en) | 2000-01-13 | 2009-03-04 | Genentech, Inc. | Human stra6 polypeptides |
US7029700B2 (en) * | 2000-01-14 | 2006-04-18 | Brown University Research Foundation | Micronized freeze-dried particles |
US6358513B1 (en) | 2000-02-15 | 2002-03-19 | Allergan Sales, Inc. | Method for treating Hashimoto's thyroiditis |
US6773711B2 (en) * | 2000-02-15 | 2004-08-10 | Allergan, Inc. | Botulinum toxin therapy for Hashimoto's thyroiditis |
US6821520B2 (en) * | 2000-02-15 | 2004-11-23 | Allergan, Inc. | Clostridial toxin therapy for Hashimoto's thyroiditis |
US6524580B1 (en) | 2000-02-15 | 2003-02-25 | Allergan Sales, Inc. | Method for treating thyroid disorders |
US6328977B1 (en) | 2000-02-22 | 2001-12-11 | Allergan Sales, Inc. | Method for treating hyperparathyroidism |
US20030211974A1 (en) * | 2000-03-21 | 2003-11-13 | Brodbeck Kevin J. | Gel composition and methods |
US6740520B2 (en) | 2000-03-21 | 2004-05-25 | Genentech, Inc. | Cytokine receptor and nucleic acids encoding the same |
US20040086970A1 (en) * | 2000-03-22 | 2004-05-06 | Genentech, Inc. | Novel cytokine receptors and nucleic acids encoding the same |
ES2266187T3 (en) * | 2000-03-24 | 2007-03-01 | Genentech, Inc. | USE OF INSULIN FOR THE TREATMENT OF CARTILAGO DISORDERS. |
US6998137B2 (en) * | 2000-04-07 | 2006-02-14 | Macromed, Inc. | Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix |
ES2525087T5 (en) * | 2000-05-10 | 2018-06-28 | Novartis Ag | Phospholipid-based powders for drug administration |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
US6264987B1 (en) | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
US20040170665A1 (en) * | 2000-06-02 | 2004-09-02 | Allergan, Inc. | Intravitreal botulinum toxin implant |
US20050214327A1 (en) * | 2000-06-02 | 2005-09-29 | Allergan, Inc. | Neurotoxin-containing suppositories and related methods |
US20040033241A1 (en) * | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
AU6531101A (en) | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
KR100381382B1 (en) * | 2000-06-28 | 2003-04-23 | 한국과학기술원 | Biodegradable Microparticles for the Controlled Release of Drugs and Process for Preparing the Same |
US6719970B1 (en) | 2000-07-10 | 2004-04-13 | Alkermes Controlled Therapeutics, Inc. | Method of generating cartilage |
AU2001281113B2 (en) | 2000-08-07 | 2006-07-20 | Nektar Therapeutics | Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation |
US6479065B2 (en) | 2000-08-10 | 2002-11-12 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
US6296842B1 (en) | 2000-08-10 | 2001-10-02 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
EP1355630B1 (en) * | 2000-08-15 | 2009-11-25 | The Board Of Trustees Of The University Of Illinois | Method of forming microparticles |
ATE412009T1 (en) | 2000-08-24 | 2008-11-15 | Genentech Inc | METHOD FOR INHIBITING IL-22 INDUCED PAP1 |
EP1944317A3 (en) | 2000-09-01 | 2008-09-17 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6824822B2 (en) * | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
US6471995B1 (en) | 2000-09-27 | 2002-10-29 | Alkermes Controlled Therapeutics, Inc. Ii | Apparatus and method for preparing microparticles using liquid-liquid extraction |
ES2326209T3 (en) | 2000-10-27 | 2009-10-05 | Baxter Healthcare S.A. | MICRO SPHERES PRODUCTION. |
US6673580B2 (en) * | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
US8394813B2 (en) | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
SE518008C2 (en) * | 2000-11-16 | 2002-08-13 | Bioglan Ab | Microparticles containing biologically active compound useful in controlled release comprise a biodegradable starch as a matrix containing biologically active substance |
US20020114843A1 (en) * | 2000-12-27 | 2002-08-22 | Ramstack J. Michael | Preparation of microparticles having improved flowability |
US20070142325A1 (en) * | 2001-01-08 | 2007-06-21 | Gustavsson Nils O | Starch |
US20040022861A1 (en) * | 2001-01-30 | 2004-02-05 | Williams Robert O. | Process for production of nanoparticles and microparticles by spray freezing into liquid |
WO2002067991A1 (en) * | 2001-02-23 | 2002-09-06 | Genentech, Inc. | Erodible polymers for injection |
FR2822834B1 (en) * | 2001-04-02 | 2005-02-25 | Flamel Tech Sa | COLLOIDAL SUSPENSION OF NANOPARTICLES BASED ON AMPHIPHILIC COPOLYMERS FOR VECTORIZATION OF ACTIVE INGREDIENTS AND THEIR METHOD OF PREPARATION |
US6558702B2 (en) * | 2001-04-13 | 2003-05-06 | Alkermes Controlled Therapeutics, Inc. | Method of modifying the release profile of sustained release compositions |
US20060269602A1 (en) * | 2001-04-13 | 2006-11-30 | Dasch James R | Method of modifying the release profile of sustained release compositions |
US6887857B2 (en) * | 2001-04-27 | 2005-05-03 | Scimed Life Systems, Inc. | Microparticle protection of therapeutic agents |
AU2002342653A1 (en) * | 2001-05-14 | 2002-11-25 | The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health | Modified growth hormone |
US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
DK1418890T3 (en) * | 2001-08-16 | 2008-08-11 | Baxter Int | Propellant-based microparticle formulations |
US20080026068A1 (en) * | 2001-08-16 | 2008-01-31 | Baxter Healthcare S.A. | Pulmonary delivery of spherical insulin microparticles |
US7169752B2 (en) * | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
US20060014697A1 (en) * | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
EP1446104B2 (en) * | 2001-11-01 | 2011-08-03 | Novartis AG | Spray drying methods |
US20070196415A1 (en) * | 2002-11-14 | 2007-08-23 | Guohua Chen | Depot compositions with multiple drug release rate controls and uses thereof |
DE60239556D1 (en) * | 2001-11-14 | 2011-05-05 | Durect Corp | CATHETERINJICIBLE DEPOT COMPOSITIONS AND THEIR USE |
KR20040058100A (en) * | 2001-11-14 | 2004-07-03 | 알자 코포레이션 | Injectable depot compositions and uses thereof |
ES2364636T3 (en) | 2001-12-19 | 2011-09-08 | Novartis Ag | PULMONARY ADMINISTRATION OF AMINOGLUCOSIDS. |
US7255874B1 (en) | 2001-12-21 | 2007-08-14 | Closure Medical Corporation | Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto |
AU2003217367B2 (en) * | 2002-02-08 | 2005-09-08 | Alkermes Controlled Therapeutics, Inc. | Polymer-based compositions for sustained release |
JP2005518212A (en) | 2002-02-25 | 2005-06-23 | ジェネンテック・インコーポレーテッド | Novel type 1 cytokine receptor GLM-R |
AU2003220562A1 (en) * | 2002-04-01 | 2003-10-20 | Peter K. Law | Cellular transplantation for heart regeneration |
FR2840614B1 (en) | 2002-06-07 | 2004-08-27 | Flamel Tech Sa | POLYAMINOACIDS FUNCTIONALIZED BY ALPHA-TOCOPHEROL AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
AR039729A1 (en) | 2002-06-25 | 2005-03-09 | Alza Corp | SHORT-TERM DEPOSIT FORMULATIONS |
FR2843117B1 (en) * | 2002-07-30 | 2004-10-15 | Flamel Tech Sa | POLYAMINOACIDS FUNCTIONALIZED BY AT LEAST ONE HYDROPHOBIC GROUP AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS |
CA2494342A1 (en) * | 2002-07-31 | 2004-02-12 | Alza Corporation | Injectable depot compositions and uses thereof |
DE60325742D1 (en) | 2002-07-31 | 2009-02-26 | Alza Corp | INJECTABLE MULTIMODAL POLYMERS DEPOT COMPOSITIONS AND THEIR USES |
NZ539810A (en) * | 2002-11-06 | 2008-03-28 | Alza Corp | Controlled release injectable depot formulations |
JP4686361B2 (en) * | 2002-12-31 | 2011-05-25 | アルタス ファーマシューティカルズ インコーポレイテッド | Crystals of human growth hormone and method for preparing the same |
PT2335725T (en) | 2003-04-04 | 2017-01-06 | Novartis Ag | High concentration antibody and protein formulations |
DE10315538A1 (en) * | 2003-04-04 | 2004-10-21 | Siemens Ag | Particles with a membrane |
ATE390126T1 (en) * | 2003-05-01 | 2008-04-15 | Ltt Bio Pharma Co Ltd | DELAYED RELEASE PREPARATIONS CONTAINING ZINC AND PRODUCTION THEREOF |
FR2855521B1 (en) * | 2003-05-28 | 2005-08-05 | Flamel Tech Sa | POLYAMINOACIDES FUNCTIONALIZED BY AT LEAST ONE YDROPHOBIC GROUP AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS. |
AU2004245022A1 (en) * | 2003-05-30 | 2004-12-16 | Alza Corporation | Implantable elastomeric depot compositions, uses thereof and method of manufacturing |
US20070184084A1 (en) * | 2003-05-30 | 2007-08-09 | Guohua Chen | Implantable elastomeric caprolactone depot compositions and uses thereof |
JP2007526447A (en) | 2003-06-06 | 2007-09-13 | ジェネンテック・インコーポレーテッド | Regulation of interaction between HGF β chain and C-MET |
PL1641822T3 (en) | 2003-07-08 | 2013-10-31 | Genentech Inc | Il-17 a/f heterologous polypeptides and therapeutic uses thereof |
US20050142205A1 (en) * | 2003-07-18 | 2005-06-30 | Julia Rashba-Step | Methods for encapsulating small spherical particles prepared by controlled phase separation |
SG135204A1 (en) * | 2003-07-18 | 2007-09-28 | Baxter Int | Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation |
US20070092452A1 (en) * | 2003-07-18 | 2007-04-26 | Julia Rashba-Step | Methods for fabrication, uses, compositions of inhalable spherical particles |
EP1646354A4 (en) * | 2003-07-22 | 2010-03-17 | Baxter Int | Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof |
FR2860516B1 (en) * | 2003-10-03 | 2006-01-13 | Flamel Tech Sa | TELECHELIC HOMOPOLYAMINOACIDES FUNCTIONALIZED BY HYDROPHOBIC GROUPS AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS |
US20050118206A1 (en) * | 2003-11-14 | 2005-06-02 | Luk Andrew S. | Surfactant-based gel as an injectable, sustained drug delivery vehicle |
US20050281879A1 (en) * | 2003-11-14 | 2005-12-22 | Guohua Chen | Excipients in drug delivery vehicles |
FR2862536B1 (en) * | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | PHARMACEUTICAL FORMULATIONS FOR THE PROLONGED DELIVERY OF ACTIVE (S) PRINCIPLE (S) AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS |
FR2862541B1 (en) * | 2003-11-21 | 2007-04-20 | Flamel Tech Sa | PHARMACEUTICAL FORMULATIONS FOR PROLONGED RELEASE OF INTERFERONS AND THEIR THERAPEUTIC APPLICATIONS |
FR2862535B1 (en) * | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | PHARMACEUTICAL FORMULATIONS FOR PROLONGED RELEASE OF INTERLEUKINS AND THEIR THERAPEUTIC APPLICATIONS |
US7309500B2 (en) * | 2003-12-04 | 2007-12-18 | The Board Of Trustees Of The University Of Illinois | Microparticles |
CA2548282A1 (en) | 2003-12-11 | 2005-06-30 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
US7481997B1 (en) | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
AU2005229434B2 (en) | 2004-03-30 | 2010-09-30 | Nsgene A/S | Therapeutic use of a growth factor, NsG33 |
PL1734971T3 (en) | 2004-04-15 | 2012-08-31 | Alkermes Pharma Ireland Ltd | Polymer-based sustained release device |
CA2563957A1 (en) * | 2004-04-23 | 2005-11-10 | Amgen Inc. | Low molecular weight polylactic acid polymers |
US20050260272A1 (en) * | 2004-05-05 | 2005-11-24 | Alkermes Controlled Therapeutics, Inc. | Method of forming microparticles that include a bisphosphonate and a polymer |
US7815941B2 (en) | 2004-05-12 | 2010-10-19 | Baxter Healthcare S.A. | Nucleic acid microspheres, production and delivery thereof |
CN103432079A (en) * | 2004-05-12 | 2013-12-11 | 巴克斯特国际公司 | Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1 |
WO2005112893A1 (en) | 2004-05-12 | 2005-12-01 | Baxter International Inc. | Microspheres comprising protein and showing injectability at high concentrations of said agent |
US8728525B2 (en) | 2004-05-12 | 2014-05-20 | Baxter International Inc. | Protein microspheres retaining pharmacokinetic and pharmacodynamic properties |
US20090136552A1 (en) * | 2004-07-30 | 2009-05-28 | Mette Gronborg | Growth factors nsg28, nsg30, and nsg32 |
ES2432556T3 (en) | 2004-08-04 | 2013-12-04 | Evonik Corporation | Methods for manufacturing supply devices and their devices |
PT1786400E (en) * | 2004-08-12 | 2009-06-19 | Quest Pharmaceutical Services | Pharmaceutical compositions for controlled release delivery of biologically active compounds |
KR101058467B1 (en) | 2004-10-27 | 2011-08-24 | 유니버시티 오브 덴버 | Cortical Stimulating Hormone Analogs and Related Methods |
US7748343B2 (en) | 2004-11-22 | 2010-07-06 | The Board Of Trustees Of The University Of Illinois | Electrohydrodynamic spraying system |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006102659A2 (en) * | 2005-03-23 | 2006-09-28 | Nektar Therapeutics Al, Corporation | CONJUGATES OF AN hGH MOIETY AND A POLYMER |
CA2604225A1 (en) * | 2005-04-27 | 2006-11-02 | Baxter International Inc. | Surface-modified microparticles and methods of forming and using the same |
US20060271262A1 (en) * | 2005-05-24 | 2006-11-30 | Mclain Harry P Iii | Wireless agricultural network |
CA2610709A1 (en) | 2005-06-06 | 2006-12-14 | Genentech, Inc. | Transgenic models for different genes and their use for gene characterization |
WO2008018854A2 (en) * | 2005-06-06 | 2008-02-14 | The Rockefeller University | Bactiophage lysins for bacillus anthracis |
CA2607901C (en) | 2005-06-13 | 2016-08-16 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine |
PL2314623T3 (en) | 2005-06-21 | 2012-11-30 | Xoma Us Llc | IL-1beta binding antibodies and fragments thereof |
US20070015689A1 (en) * | 2005-06-23 | 2007-01-18 | Alza Corporation | Complexation of metal ions with polypeptides |
US7582291B2 (en) * | 2005-06-30 | 2009-09-01 | The Rockefeller University | Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria |
WO2007021423A2 (en) | 2005-08-15 | 2007-02-22 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
US8362086B2 (en) | 2005-08-19 | 2013-01-29 | Merial Limited | Long acting injectable formulations |
CA2620903A1 (en) * | 2005-08-24 | 2007-03-01 | The Rockefeller University | Ply-gbs mutant lysins |
JP2009516514A (en) | 2005-11-21 | 2009-04-23 | ジェネンテック・インコーポレーテッド | Novel gene disruptions, compositions and methods related thereto |
EP2336164A1 (en) | 2005-12-22 | 2011-06-22 | Genentech, Inc. | Recombinant production of heparin binding proteins |
US20090023629A1 (en) * | 2005-12-23 | 2009-01-22 | Altus Pharmaceuticals Inc. | Compositions comprising polycation-complexed protein crystals and methods of treatment using them |
ZA200807714B (en) | 2006-02-17 | 2010-01-27 | Genentech Inc | Gene disruptions, compositions and methods relating thereto |
MX2008012013A (en) | 2006-03-23 | 2008-10-03 | Novartis Ag | Anti-tumor cell antigen antibody therapeutics. |
WO2007121147A2 (en) | 2006-04-10 | 2007-10-25 | Genentech, Inc. | Disheveled pdz modulators |
US20090288176A1 (en) | 2006-04-19 | 2009-11-19 | Genentech, Inc. | Novel Gene Disruptions, Compositions and Methods Relating Thereto |
US20070281031A1 (en) * | 2006-06-01 | 2007-12-06 | Guohan Yang | Microparticles and methods for production thereof |
CN105168146A (en) * | 2006-08-04 | 2015-12-23 | 巴克斯特国际公司 | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
CN102274557B (en) | 2006-08-09 | 2014-12-03 | 精达制药公司 | Osmotic delivery systems and piston assemblies |
US20080248122A1 (en) * | 2006-10-06 | 2008-10-09 | Baxter International Inc. | Microencapsules Containing Surface-Modified Microparticles And Methods Of Forming And Using The Same |
US7695718B2 (en) | 2006-12-20 | 2010-04-13 | Xoma Technology Ltd. | Methods for the treatment of IL-1β related diseases |
WO2008118712A1 (en) * | 2007-03-22 | 2008-10-02 | Alkermes, Inc. | Coacervation process |
AU2008242842B2 (en) * | 2007-04-17 | 2014-06-05 | Baxter Healthcare Sa | Nucleic acid microparticles for pulmonary delivery |
NZ580447A (en) | 2007-04-23 | 2011-06-30 | Intarcia Therapeutics Inc | Suspension formulations of insulinotropic peptides and uses thereof |
US20080264641A1 (en) * | 2007-04-30 | 2008-10-30 | Slabaugh Billy F | Blending Fracturing Gel |
US20080317865A1 (en) * | 2007-06-20 | 2008-12-25 | Alkermes, Inc. | Quench liquids and washing systems for production of microparticles |
CN101361968B (en) | 2007-08-06 | 2011-08-03 | 健能隆医药技术(上海)有限公司 | Use of interleukin-22 in treating fatty liver |
CN103298935A (en) * | 2007-08-15 | 2013-09-11 | 阿穆尼克斯公司 | Compositions and methods for modifying properties of biologically active polypeptides |
US20090061009A1 (en) * | 2007-08-29 | 2009-03-05 | Joseph Schwarz | Composition and Method of Treatment of Bacterial Infections |
EP2222281B1 (en) | 2007-12-20 | 2018-12-05 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
MX2010006823A (en) | 2007-12-20 | 2010-09-30 | Xoma Technology Ltd | Methods for the treatment of gout. |
CA2726861C (en) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
US9107815B2 (en) | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
US20110182946A1 (en) * | 2008-03-17 | 2011-07-28 | Board Of Regents, The University Of Texas System | Formation of Nanostructured Particles of Poorly Water Soluble Drugs and Recovery by Mechanical Techniques |
AU2009270695A1 (en) | 2008-07-17 | 2010-01-21 | Ap Pharma | Methods for enhancing the stability of polyorthoesters and their formulations |
US20100047292A1 (en) * | 2008-08-20 | 2010-02-25 | Baxter International Inc. | Methods of processing microparticles and compositions produced thereby |
US8323615B2 (en) * | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing multi-phasic dispersions |
US8367427B2 (en) * | 2008-08-20 | 2013-02-05 | Baxter International Inc. | Methods of processing compositions containing microparticles |
US8323685B2 (en) | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing compositions containing microparticles |
US20100189800A1 (en) * | 2009-01-23 | 2010-07-29 | Peter Markland | Continous double emulsion process for making microparticles |
MX2011008094A (en) | 2009-02-03 | 2012-02-13 | Amunix Operating Inc | Extended recombinant polypeptides and compositions comprising same. |
US8680050B2 (en) * | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
US8703717B2 (en) * | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
BRPI1006443B1 (en) | 2009-04-22 | 2021-05-25 | Alteogen, Inc | FUSION PROTEIN OR PEPTIDE AND METHOD TO INCREASE THE IN VIVO HALF-LIFE OF A PROTEIN OR PEPTIDE |
US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
CA2775676C (en) | 2009-09-28 | 2016-08-16 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
EP2488643A4 (en) * | 2009-10-15 | 2013-07-03 | Hoffmann La Roche | Chimeric fibroblast growth factors with altered receptor specificity |
US8771693B2 (en) | 2009-10-27 | 2014-07-08 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
US8637637B2 (en) * | 2010-01-12 | 2014-01-28 | Bill Nai-Chau Sun | Fc fusion proteins of human growth hormone |
KR20120113265A (en) | 2010-01-15 | 2012-10-12 | 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 | Use of vanadium compounds to accelerate bone healing |
CA3027749A1 (en) | 2010-03-22 | 2011-09-29 | Junyan Ji | Compositions and methods useful for stabilizing protein-containing formulations |
CA2794864A1 (en) | 2010-05-03 | 2011-11-10 | Genentech, Inc. | Compositions and methods useful for reducing the viscosity of protein-containing formulations |
EP2585045B1 (en) | 2010-06-24 | 2019-08-21 | F.Hoffmann-La Roche Ag | Compositions and methods containing alkylgycosides for stabilizing protein-containing formulations |
CN102380091A (en) | 2010-08-31 | 2012-03-21 | 健能隆医药技术(上海)有限公司 | Application of interleukin-22 in curing virus hepatitis |
WO2012041328A1 (en) | 2010-10-01 | 2012-04-05 | Nsgene A/S | Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain |
EP2624852B1 (en) | 2010-10-08 | 2016-12-14 | Shanghai Kexin Biotech Co., Ltd | Diagnostic and therapeutic uses of moesin fragments |
WO2012045274A1 (en) | 2010-10-08 | 2012-04-12 | Shanghai Kexin Biotech Co., Ltd. | Moesin modulators and uses thereof |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
US10487114B2 (en) | 2011-04-27 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof |
LT3091029T (en) | 2011-10-31 | 2023-02-27 | F. Hoffmann-La Roche Ag | Anti-il13 antibody formulations |
CN104144946A (en) | 2011-12-19 | 2014-11-12 | 爱克索马美国有限责任公司 | Methods for treating acne |
JP2015509091A (en) | 2012-01-09 | 2015-03-26 | ザ スクリプス リサーチ インスティテュート | Humanized antibody |
WO2013106485A2 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
EP2846772A4 (en) | 2012-05-10 | 2015-12-30 | Painreform Ltd | Depot formulations of a hydrophobic active ingredient and methods for preparation thereof |
AU2014240063B2 (en) | 2013-03-15 | 2019-04-11 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
US20160168231A1 (en) | 2013-07-18 | 2016-06-16 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
WO2015010100A2 (en) | 2013-07-18 | 2015-01-22 | Fabrus, Inc. | Humanized antibodies with ultralong complementarity determining regions |
EP3043824B1 (en) | 2013-09-13 | 2022-07-06 | The Scripps Research Institute | Modified therapeutic agents and compositions thereof |
CN105814083A (en) | 2013-10-15 | 2016-07-27 | 加州生物医学研究所 | Chimeric antigen receptor T cell switches and uses thereof |
ES2845924T3 (en) | 2013-10-15 | 2021-07-28 | Scripps Research Inst | T-cell switches with peptide chimeric antigen receptors and their uses |
CN104623639A (en) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Application of interleukin-22 dimer in preparation of drugs for treating pancreatitis |
CN104623637A (en) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Application of IL-22 dimer in preparation of intravenous injection drugs |
CA2931547A1 (en) | 2013-12-09 | 2015-06-18 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
WO2015095406A1 (en) | 2013-12-18 | 2015-06-25 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
NL2014230B1 (en) | 2015-02-04 | 2016-10-12 | Stichting Vu-Vumc | Wound healing formulation. |
MA41629A (en) | 2015-03-04 | 2018-01-09 | Center For Human Reproduction | COMPOSITIONS AND METHODS OF USE OF ANTI-MÜLLERIAN HORMONE FOR THE TREATMENT OF INFERTILITY |
WO2016154621A1 (en) | 2015-03-26 | 2016-09-29 | The California Institute For Biomedical Research | SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF |
WO2016168773A2 (en) | 2015-04-15 | 2016-10-20 | The California Institute For Biomedical Research | Optimized pne-based chimeric receptor t cell switches and uses thereof |
CN113598842A (en) | 2015-06-03 | 2021-11-05 | 因塔西亚制药公司 | Implant placement and removal system |
US20190000928A1 (en) | 2015-06-17 | 2019-01-03 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
EP3442562B1 (en) | 2016-04-15 | 2022-09-21 | Evive Biotechnology (Shanghai) Ltd | An il-22 dimer for use in treating necrotizing enterocolitis |
EP3458084B1 (en) | 2016-05-16 | 2020-04-01 | Intarcia Therapeutics, Inc | Glucagon-receptor selective polypeptides and methods of use thereof |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
JP7149935B2 (en) | 2016-10-19 | 2022-10-07 | ザ スクリプス リサーチ インスティテュート | Chimeric Antigen Receptor Effector Cell Switches with Humanized Targeting Moieties and/or Optimized Chimeric Antigen Receptor Interacting Domains and Uses Thereof |
KR20190104039A (en) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Methods Including Continuous Administration of GLP-1 Receptor Agonists and Co-administration of Drugs |
CA3133652A1 (en) | 2019-04-01 | 2020-10-08 | Genentech, Inc. | Compositions and methods for stabilizing protein-containing formulations |
AU2020328507A1 (en) | 2019-08-12 | 2022-03-17 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells |
EP4048405A2 (en) | 2019-10-24 | 2022-08-31 | Minotaur Therapeutics, Inc. | Chimeric cytokine modified antibodies and methods of use thereof |
WO2021146215A1 (en) | 2020-01-13 | 2021-07-22 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
EP4329887A1 (en) | 2021-04-28 | 2024-03-06 | Minotaur Therapeutics, Inc. | Humanized chimeric bovine antibodies and methods of use |
WO2022233989A1 (en) | 2021-05-06 | 2022-11-10 | Hoba Therapeutics Aps | Prevention and treatment of chemotherapy-induced neuropathic pain |
WO2023104960A1 (en) | 2021-12-10 | 2023-06-15 | Hoba Therapeutics Aps | Treatment of nociceptive pain |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0330180A1 (en) * | 1988-02-24 | 1989-08-30 | Biomaterials Universe, Inc. | Polylactic acid type microspheres containing physiologically active substance and process for preparing the same |
WO1990013780A1 (en) * | 1989-05-01 | 1990-11-15 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
WO1993017668A1 (en) * | 1992-03-12 | 1993-09-16 | Alkermes Controlled Therapeutics, Inc. | Controlled release acth containing microspheres |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4906474A (en) * | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
US4891225A (en) * | 1984-05-21 | 1990-01-02 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
US4985404A (en) * | 1984-10-04 | 1991-01-15 | Monsanto Company | Prolonged release of biologically active polypeptides |
US4962091A (en) * | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
US4981696A (en) * | 1986-12-22 | 1991-01-01 | E. I. Du Pont De Nemours And Company | Polylactide compositions |
US4853218A (en) * | 1987-02-24 | 1989-08-01 | Schering Corporation | Zinc-protamine-alpha interferon complex |
GB8712176D0 (en) * | 1987-05-22 | 1987-06-24 | Cosmas Damian Ltd | Drug delivery system |
US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
US4990336A (en) * | 1989-02-08 | 1991-02-05 | Biosearch, Inc. | Sustained release dosage form |
US5122367A (en) * | 1989-03-31 | 1992-06-16 | Massachusetts Institute Of Technology | Polyanhydride bioerodible controlled release implants for administration of stabilized growth hormone |
US5126147A (en) * | 1990-02-08 | 1992-06-30 | Biosearch, Inc. | Sustained release dosage form |
FR2658432B1 (en) * | 1990-02-22 | 1994-07-01 | Medgenix Group Sa | MICROSPHERES FOR THE CONTROLLED RELEASE OF WATER-SOLUBLE SUBSTANCES AND PREPARATION METHOD. |
JPH07503700A (en) * | 1991-01-03 | 1995-04-20 | アルカーメス コントロールド セラピューティックス, インコーポレイテッド | Protein stabilization with cationic biopolymers |
GB9116610D0 (en) * | 1991-08-01 | 1991-09-18 | Danbiosyst Uk | Preparation of microparticles |
US5176907A (en) * | 1991-08-13 | 1993-01-05 | The Johns Hopkins University School Of Medicine | Biocompatible and biodegradable poly (phosphoester-urethanes) |
AU2605592A (en) * | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US5288502A (en) * | 1991-10-16 | 1994-02-22 | The University Of Texas System | Preparation and uses of multi-phase microspheres |
US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
ATE222500T1 (en) * | 1992-06-11 | 2002-09-15 | Alkermes Inc | ENYTHROPOIETIN CONTAINING DRUG DELIVERY SYSTEM |
WO1994012158A1 (en) * | 1992-12-02 | 1994-06-09 | Alkermes Controlled Therapeutics, Inc. | Controlled release growth hormone containing microspheres |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
AUPM784894A0 (en) * | 1994-09-02 | 1994-09-29 | Murchie, Barry Joseph | Baby's breathing aid |
CN1157562A (en) * | 1994-09-09 | 1997-08-20 | 武田药品工业株式会社 | Sustained release preparation containing metal salt of peptide |
-
1993
- 1993-12-02 WO PCT/US1993/011621 patent/WO1994012158A1/en active IP Right Grant
- 1993-12-02 DE DE69329295T patent/DE69329295T2/en not_active Expired - Fee Related
- 1993-12-02 AT AT94902475T patent/ATE195652T1/en not_active IP Right Cessation
- 1993-12-02 JP JP6513463A patent/JPH08503950A/en not_active Ceased
- 1993-12-02 DK DK94902475T patent/DK0674506T3/en active
- 1993-12-02 EP EP00101570A patent/EP1013270A3/en not_active Withdrawn
- 1993-12-02 AU AU56835/94A patent/AU670168B2/en not_active Ceased
- 1993-12-02 EP EP94902475A patent/EP0674506B1/en not_active Expired - Lifetime
- 1993-12-02 PT PT94902475T patent/PT674506E/en unknown
- 1993-12-02 CA CA002150803A patent/CA2150803C/en not_active Expired - Fee Related
- 1993-12-02 ES ES94902475T patent/ES2151541T3/en not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/473,544 patent/US5654010A/en not_active Expired - Fee Related
- 1995-06-07 US US08/477,725 patent/US5667808A/en not_active Expired - Fee Related
-
1996
- 1996-06-03 KR KR1019970708517A patent/KR19990022038A/en not_active Application Discontinuation
- 1996-10-04 AU AU68029/96A patent/AU694378B2/en not_active Ceased
-
1998
- 1998-03-02 US US09/033,193 patent/US5891478A/en not_active Expired - Fee Related
-
1999
- 1999-02-19 US US09/252,746 patent/US6051259A/en not_active Expired - Fee Related
-
2000
- 2000-02-17 US US09/505,508 patent/US6500448B1/en not_active Expired - Fee Related
- 2000-11-16 GR GR20000402562T patent/GR3034873T3/en not_active IP Right Cessation
-
2002
- 2002-10-29 US US10/284,428 patent/US20030211153A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0330180A1 (en) * | 1988-02-24 | 1989-08-30 | Biomaterials Universe, Inc. | Polylactic acid type microspheres containing physiologically active substance and process for preparing the same |
WO1990013780A1 (en) * | 1989-05-01 | 1990-11-15 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
WO1993017668A1 (en) * | 1992-03-12 | 1993-09-16 | Alkermes Controlled Therapeutics, Inc. | Controlled release acth containing microspheres |
Cited By (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5912015A (en) * | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US6368630B1 (en) | 1992-03-12 | 2002-04-09 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US6749866B2 (en) | 1992-03-12 | 2004-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
US6514533B1 (en) | 1992-06-11 | 2003-02-04 | Alkermas Controlled Therapeutics, Inc. | Device for the sustained release of aggregation-stabilized, biologically active agent |
US5716644A (en) * | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
US5674534A (en) * | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
US6051259A (en) * | 1992-12-02 | 2000-04-18 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of human growth hormone |
US5654010A (en) * | 1992-12-02 | 1997-08-05 | Alkermes, Inc. | Composition for sustained release of human growth hormone |
US6500448B1 (en) | 1992-12-02 | 2002-12-31 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of human growth hormone |
US5667808A (en) * | 1992-12-02 | 1997-09-16 | Alkermes, Inc. | Composition for sustained release of human growth hormone |
US5891478A (en) * | 1992-12-02 | 1999-04-06 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of human growth hormone |
US6087324A (en) * | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6376461B1 (en) | 1993-06-24 | 2002-04-23 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
WO1995029664A1 (en) * | 1994-05-03 | 1995-11-09 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US6165508A (en) * | 1994-07-25 | 2000-12-26 | Alkermes Controlled Therapeutics, Inc. | Controlled release of metal cation-stabilized interferon |
US5711968A (en) * | 1994-07-25 | 1998-01-27 | Alkermes Controlled Therapeutics, Inc. | Composition and method for the controlled release of metal cation-stabilized interferon |
US6379701B1 (en) | 1994-07-25 | 2002-04-30 | Alkermes Controlled Therapeutics, Inc. | Controlled release of metal cation-stabilized interferon |
US6780434B2 (en) | 1994-07-25 | 2004-08-24 | Alkermes Controlled Therapeutics, Inc. | Controlled release of metal cation-stabilized interferon |
AU695323B2 (en) * | 1994-09-09 | 1998-08-13 | Takeda Chemical Industries Ltd. | Sustained release preparation containing metal salt of a peptide |
KR100356550B1 (en) * | 1994-09-09 | 2002-12-18 | 다케다 야쿠힌 고교 가부시키가이샤 | Sustained release preparation containing metal salt of a peptide |
WO1996007399A1 (en) * | 1994-09-09 | 1996-03-14 | Takeda Chemical Industries, Ltd. | Sustained release preparation containing metal salt of a peptide |
EP1002529A1 (en) * | 1994-09-09 | 2000-05-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation containing a metal salt of a peptide |
WO1996040074A2 (en) * | 1995-06-07 | 1996-12-19 | Alkermes Controlled Therapeutics, Inc. | Device for releasing aggregation-stabilized, biologically active agent |
WO1996040074A3 (en) * | 1995-06-07 | 1997-02-06 | Alkermes Inc | Device for releasing aggregation-stabilized, biologically active agent |
WO1996040072A3 (en) * | 1995-06-07 | 1997-01-23 | Alkermes Inc | Composition for sustained release of human growth hormone |
WO1996040072A2 (en) * | 1995-06-07 | 1996-12-19 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of human growth hormone |
EP1080718A1 (en) * | 1995-06-07 | 2001-03-07 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of human growth hormone |
CN1102854C (en) * | 1995-06-07 | 2003-03-12 | 阿尔克姆斯控制治疗公司 | Composition for sustained release of human growth hormone |
US6267981B1 (en) | 1995-06-27 | 2001-07-31 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
US5916597A (en) * | 1995-08-31 | 1999-06-29 | Alkermes Controlled Therapeutics, Inc. | Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent |
WO1997007788A3 (en) * | 1995-08-31 | 1997-04-17 | Alkermes Inc | Composition for sustained release of an agent |
WO1997007788A2 (en) * | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
US6120787A (en) * | 1995-10-19 | 2000-09-19 | Biogram Ab | Sustained release particles |
AU679150B1 (en) * | 1996-01-10 | 1997-06-19 | Lg Chemical Ltd. | Sustained-release formulation of animal growth hormone and process for preparation thereof |
US6190702B1 (en) | 1996-03-28 | 2001-02-20 | Takeda Chemical Industries, Ltd. | Sustained-released material prepared by dispersing a lyophilized polypeptide in an oil phase |
EP1070502A3 (en) * | 1996-12-02 | 2001-10-17 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing inflammatory diseases |
US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
EP1090637A3 (en) * | 1996-12-02 | 2001-09-12 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing inflammatory diseases |
EP1092433A3 (en) * | 1996-12-02 | 2001-09-12 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing inflammatory diseases |
EP1090637A2 (en) * | 1996-12-02 | 2001-04-11 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing inflammatory diseases |
WO1998024427A2 (en) * | 1996-12-02 | 1998-06-11 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing inflammatory diseases |
US6689803B2 (en) | 1996-12-02 | 2004-02-10 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating surgical adhesions |
EP1092433A2 (en) * | 1996-12-02 | 2001-04-18 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing inflammatory diseases |
EP1070502A2 (en) * | 1996-12-02 | 2001-01-24 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing inflammatory diseases |
US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
WO1998024427A3 (en) * | 1996-12-02 | 1998-10-01 | Angiotech Pharm Inc | Compositions and methods for treating or preventing inflammatory diseases |
WO1998027980A3 (en) * | 1996-12-20 | 1998-08-13 | Takeda Chemical Industries Ltd | Method of producing a sustained-release preparation |
WO1998027980A2 (en) * | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
US6197350B1 (en) | 1996-12-20 | 2001-03-06 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
US6399103B1 (en) | 1996-12-20 | 2002-06-04 | Takeda Chemical Industries, Inc. | Method of producing a sustained-release preparation |
US6770624B2 (en) | 1997-06-04 | 2004-08-03 | The Regents Of The University Of California | Treatment of heart failure with growth hormone |
US6306826B1 (en) | 1997-06-04 | 2001-10-23 | The Regents Of The University Of California | Treatment of heart failure with growth hormone |
US6191107B1 (en) | 1997-09-26 | 2001-02-20 | Takeda Chemical Industries, Ltd. | Complex of human growth hormone and zinc |
US6429296B2 (en) | 1997-09-26 | 2002-08-06 | Takeda Chemical Industries, Ltd. | Complex of human growth hormone and zinc and use |
US6573238B2 (en) | 1997-11-07 | 2003-06-03 | Chiron Corporation | Method for producing sustained-release formulations |
US6482864B1 (en) | 1998-03-20 | 2002-11-19 | Takeda Chemical Industries, Ltd. | Sustained-release preparation of physiologically active polypeptide and production thereof |
EP2286792A1 (en) | 1999-02-26 | 2011-02-23 | Novartis Vaccines and Diagnostics, Inc. | Microemulsions with an adsorbent surface, comprising a microdroplet emulsion |
WO2000052049A2 (en) * | 1999-03-01 | 2000-09-08 | Alkermes Controlled Therapeutics, Inc. | A method for purifying human growth hormone |
WO2000052049A3 (en) * | 1999-03-01 | 2000-12-21 | Alkermes Inc | A method for purifying human growth hormone |
US6451347B1 (en) | 1999-03-01 | 2002-09-17 | Alkermes Controlled Therapeutics, Inc. | Method for purifying human growth hormone |
US8097243B2 (en) | 1999-07-29 | 2012-01-17 | Novartis Vaccines And Diagnostics, Inc. | Microparticle-based transfection and activation of dendritic cells |
US6723347B1 (en) | 1999-09-17 | 2004-04-20 | Takeda Chemical Industries, Ltd. | Proces for producing protein powder |
US6992065B2 (en) | 2000-04-19 | 2006-01-31 | Genentech, Inc. | Sustained release formulations |
US6689389B2 (en) | 2000-10-06 | 2004-02-10 | Jagotec Ag | Pharmaceutically acceptable starch |
US7119195B2 (en) | 2000-10-06 | 2006-10-10 | Jagotec Ag | Pharmaceutically acceptable starch |
US6692770B2 (en) | 2000-10-06 | 2004-02-17 | Jagotec Ag | Starch microparticles |
US6706288B2 (en) | 2000-10-06 | 2004-03-16 | Jagotec Ag | Microparticles |
US7033609B2 (en) | 2000-10-06 | 2006-04-25 | Jagotec Ag | Microparticle preparation |
US6616948B2 (en) | 2000-10-06 | 2003-09-09 | Jagotec Ag | Starch |
US6616949B2 (en) | 2000-11-16 | 2003-09-09 | Jagotec Ag | Process for producing microparticles |
US7713739B1 (en) | 2000-11-17 | 2010-05-11 | Novartis Vaccines And Diagnostics, Inc. | Microparticle-based transfection and activation of dendritic cells |
WO2003000282A1 (en) * | 2001-06-21 | 2003-01-03 | Genentech, Inc. | Sustained release formulation |
US7318931B2 (en) | 2001-06-21 | 2008-01-15 | Genentech, Inc. | Sustained release formulation |
US8067020B2 (en) | 2001-06-21 | 2011-11-29 | Genetech, Inc. | Sustained release formulation |
US7105181B2 (en) | 2001-10-05 | 2006-09-12 | Jagotec, Ag | Microparticles |
US6936278B2 (en) | 2002-03-21 | 2005-08-30 | Jagotec Ag | Microparticles |
US9149440B2 (en) | 2003-09-02 | 2015-10-06 | University Of South Florida | Nanoparticles for drug-delivery |
WO2005034988A1 (en) * | 2003-10-10 | 2005-04-21 | Novo Nordisk A/S | Long-acting molecules in sustained release formulations |
EP1691826A1 (en) * | 2003-11-14 | 2006-08-23 | ALZA Corporation | Excipients in drug delivery vehicles |
EP1691826A4 (en) * | 2003-11-14 | 2012-08-22 | Alza Corp | Excipients in drug delivery vehicles |
EP2176321A2 (en) * | 2007-08-07 | 2010-04-21 | Korea Research Institute of Bioscience and Biotechnology | Porous polymer particles immobilized with charged molecules and method for preparing the same |
EP2176321A4 (en) * | 2007-08-07 | 2012-09-12 | Korea Res Inst Of Bioscience | Porous polymer particles immobilized with charged molecules and method for preparing the same |
Also Published As
Publication number | Publication date |
---|---|
ATE195652T1 (en) | 2000-09-15 |
AU5683594A (en) | 1994-06-22 |
CA2150803A1 (en) | 1994-06-09 |
PT674506E (en) | 2001-01-31 |
US5891478A (en) | 1999-04-06 |
EP0674506B1 (en) | 2000-08-23 |
US5654010A (en) | 1997-08-05 |
EP1013270A3 (en) | 2001-03-28 |
US5667808A (en) | 1997-09-16 |
DE69329295D1 (en) | 2000-09-28 |
AU6802996A (en) | 1996-12-19 |
US20030211153A1 (en) | 2003-11-13 |
US6500448B1 (en) | 2002-12-31 |
DK0674506T3 (en) | 2001-01-08 |
DE69329295T2 (en) | 2001-03-15 |
CA2150803C (en) | 2006-01-31 |
GR3034873T3 (en) | 2001-02-28 |
EP1013270A2 (en) | 2000-06-28 |
AU670168B2 (en) | 1996-07-04 |
EP0674506A1 (en) | 1995-10-04 |
ES2151541T3 (en) | 2001-01-01 |
US6051259A (en) | 2000-04-18 |
JPH08503950A (en) | 1996-04-30 |
AU694378B2 (en) | 1998-07-16 |
KR19990022038A (en) | 1999-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU670168B2 (en) | Controlled release growth hormone containing microspheres | |
EP0630234B1 (en) | Controlled release acth containing microspheres | |
EP0644771B2 (en) | Erythropoietin drug delivery system | |
US6455074B1 (en) | Methods for fabricating polymer-based controlled release devices | |
EP0424516B1 (en) | Very low temperature casting of controlled release microspheres | |
US5711968A (en) | Composition and method for the controlled release of metal cation-stabilized interferon | |
JP2670680B2 (en) | Polylactic acid microspheres containing physiologically active substance and method for producing the same | |
US20080254086A1 (en) | Controlled Release Compositions | |
PL195223B1 (en) | Composition of slowed down release of a drug being encapsulated in microparticles of hialuronic acid | |
US20080176785A1 (en) | Controlled release compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK MG MN MW NO NZ PL RO RU SD SK UA VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: PAT.BUL.13/94 UNDER PUBLISHED ADD "BEFORE THE EXPIRATION OF THE TIME LIMIT FOR AMENDING THE CLAIMS AND TO BE REPUBLISHED IN THE EVENT OF THE RECEIPT OF AMENDMENTS"; DUE TO RECALCULATION OF THE APPLICABLE TIME LIMIT UNDER RULE 80.6 |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2150803 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994902475 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1994902475 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994902475 Country of ref document: EP |